Investor Relations

MiNK presents first-of-a-kind data with allogeneic iNKTs, agenT-797, showing durable clinical benefit in solid tumor cancers and persistence >6 months without toxic pre-conditioning. AgenT-797 demonstrates potential beyond cancer, with improved survival in severe respiratory distress.

Clinical responses and durable activity with agenT-797 monotherapy and in combination with anti-PD-1 First-of-a-kind persistence for an allogeneic cell therapy, with agenT-797 detected for up to 6 months without toxic pre-conditioning AgenT-797 advancing in a randomized phase 2 trial in 2L gastric

NEW YORK , Oct. 30, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other